inVentiv Health 收购Ingenix i3 临床诊断部门
- inVentiv Health2011年1月21日 14:39 点击：3222
inVentiv Health 收购Ingenix临床诊断部门
inVentiv Health to Acquire Clinical Development Outsourcing Businesses from Ingenix
Ingenix Life Sciences Retains Commercialization,
Safety and Regulatory Businesses
SOMERSET, N.J., and EDEN PRAIRIE, Minn., Jan. 20, 2011 – inVentiv Health, a leading provider of outsourced clinical development, launch and commercial services to the global health care industry, today announced it has signed a definitive agreement to purchase the i3 clinical development businesses from Ingenix. The proposed transaction, covering businesses that generate approximately $400 million in annual gross revenue, is subject to customary closing conditions and is expected to close in the first half of this year.
Upon close of the proposed transaction, inVentiv will acquire the following businesses from Ingenix: i3 Research, i3 Statprobe and i3 Pharma Resourcing. These businesses will retain the i3 brand name and will be aligned with inVentiv’s other clinical development offerings, advancing i3’s position as a top-tier, global CRO serving pharmaceutical, biotech and medical device companies. Glenn Bilawsky will remain CEO of i3.
Ingenix will align all of its commercialization, safety, regulatory and late phase service offerings under its newly-launched Ingenix Life Sciences division, led by Lee Valenta, who has been COO of Ingenix for the past five years. Ingenix will provide additional details about Ingenix Life Sciences in a separate announcement today.
About Ingenix
Ingenix transforms organizations and improves health care through information and technology. Organizations rely on its innovative products, services and consulting to improve the delivery and operations of their business. Through its over 13,000 employees around the world, Ingenix serves physicians, hospitals, government agencies, health plans and life sciences companies. For more information about Ingenix, visit www.ingenix.com .
Safety and Regulatory Businesses
SOMERSET, N.J., and EDEN PRAIRIE, Minn., Jan. 20, 2011 – inVentiv Health, a leading provider of outsourced clinical development, launch and commercial services to the global health care industry, today announced it has signed a definitive agreement to purchase the i3 clinical development businesses from Ingenix. The proposed transaction, covering businesses that generate approximately $400 million in annual gross revenue, is subject to customary closing conditions and is expected to close in the first half of this year.
Upon close of the proposed transaction, inVentiv will acquire the following businesses from Ingenix: i3 Research, i3 Statprobe and i3 Pharma Resourcing. These businesses will retain the i3 brand name and will be aligned with inVentiv’s other clinical development offerings, advancing i3’s position as a top-tier, global CRO serving pharmaceutical, biotech and medical device companies. Glenn Bilawsky will remain CEO of i3.
Ingenix will align all of its commercialization, safety, regulatory and late phase service offerings under its newly-launched Ingenix Life Sciences division, led by Lee Valenta, who has been COO of Ingenix for the past five years. Ingenix will provide additional details about Ingenix Life Sciences in a separate announcement today.
About Ingenix
Ingenix transforms organizations and improves health care through information and technology. Organizations rely on its innovative products, services and consulting to improve the delivery and operations of their business. Through its over 13,000 employees around the world, Ingenix serves physicians, hospitals, government agencies, health plans and life sciences companies. For more information about Ingenix, visit www.ingenix.com .
全年征稿 / 资讯合作
联系邮箱：kefu@labbase.net
版权与免责声明
- 凡本网注明“来源：来宝网”的所有作品，版权均属于来宝网，转载请必须注明来宝网， https://www.labbase.net，违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品，目的在于传递更多信息，并不代表本网赞同其观点或证实其内容的真实性，不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时，必须保留本网注明的作品来源，并自负版权等法律责任。
- 如涉及作品内容、版权等问题，请在作品发表之日起一周内与本网联系，否则视为放弃相关权利。
